Listing of Claims:

1. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the oligonucleotide does not have two 5' and four 3' 2-O-methylribonucleosides and wherein the oligonucleotide does not have the sequence of SEQ ID NO: 1.

2. **(original)** The method according to claim 1, wherein the prodrug is an ester or an amide of an active compound.

3. **(currently amended)** The method according to claim 2, wherein the active compound is an anti-cancer ~~compound~~ drug.

4. **(original)** The method according to claim 3, wherein the anti-cancer drug is SN-38.

5. **(original)** The method according to claim 4, wherein the prodrug is Camptosar.

6. **(currently amended)** The method according to any one of claims 1-5, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

7. **(canceled)**

8. **(previously presented)** The method according to claim 6, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

9. **(currently amended)** The method according to claim 8, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.

10. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the the oligonucleotide is administered before the prodrug.

11. **(original)** The method according to claim 10, wherein the prodrug is an ester or an amide of an active compound.

12. **(original)** The method according to claim 11, wherein the active compound is an anti-cancer drug.

13. **(original)** The method according to claim 12, wherein the anti-cancer drug is SN-38.

14. **(original)** The method according to claim 13, wherein the prodrug is Camptosar.

15. **(currently amended)** The method according to any one of claims 10-14, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

16. **(canceled)**

17. **(original)** The method according to claim 15, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

18. **(currently amended)** The method according to claim 17, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.

19. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the prodrug is present in an amount that would not be therapeutically effective in the absence of the oligonucleotide.

20. **(original)** The method according to claim 19, wherein the prodrug is an ester or an amide of an active compound.

21. **(original)** The method according to claim 20, wherein the active compound is an anti-cancer drug.

22. **(original)** The method according to claim 21, wherein the anti-cancer drug is SN-38.

23. **(original)** The method according to claim 22, wherein the prodrug is Camptosar.

24. **(currently amended)** The method according to any one of claims 19-23, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.

25. **(canceled)**

26. **(previously presented)** The method according to claim 24, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

27. **(currently amended)** The method according to claim 26, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.